Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PNEUMOSTEM in Very Premature Infants With Early Pulmonary Arterial Hypertension
NCT07368088Phase 1Not yet recruiting
- Sponsor
- Samsung Medical Center
- Start
- Mar 2026
- Primary completion
- Dec 2026
- Modality
- Mesenchymal Stem Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pneumostem in pulmonary arterial hypertension (PAH), sponsored by Samsung Medical Center. Primary endpoints: Time point of complete reversal of cardiac shunt direction, Time to normalization of ventricular septal configuration and 10 more. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
pneumostem
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT07368088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07368088.